Current Status of Angiotensin Receptor Blocker Recalls
Why the study?
Due to the complexity of FDA recall data structured across hundreds of product rows, it remains difficult for clinicians to understand which ARB products are free of nitrosamine impurities.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Complicates safe ARB selection in hypertension care; leaves open the need for streamlined FDA tools and pharmacovigilance studies.
Key Points
Key points are not available for this paper at this time.
Cite This Study
Gunasekaran et al. (2019) studied this question.